THE PLACE OF ENZALUTAMIDE IN THE SERIAL TREATMENT OF TREATMENT-RESISTANT PROSTATE CANCER

Prostate cancer initially responds to androgen-deprivation therapy, but most patients eventually develop a castration-resistant form of disease. Enzalutamid is the superselective inhibitor of the androgen receptor (AR), which blocks several stages of the AR signal path. The drug showed significant e...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: A. A. GRITSKEVICH, S. V. MISHUGIN, I. G. RUSAKOV
Formaat: Artigo
Taal:Russo
Gepubliceerd in: Remedium Group LLC 2017-06-01
Reeks:Медицинский совет
Onderwerpen:
metastatic cancer
enzalutamide
abiraterone acetate
castration resistance
Online toegang:https://www.med-sovet.pro/jour/article/view/1894
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items